Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Oligodendroglioma 1Neoplasms, Plasma Cell 1Lymphoma 1Leukemia 1Hodgkin Disease 1Hematologic Neoplasms 1Gliosarcoma 1Glioma 1Glioblastoma 1Central Nervous System Neoplasms 1Astrocytoma 1

Interventions

Temozolomide 85Radiotherapy 51Bevacizumab 31Irinotecan 19Radiation 16Carmustine 15Magnetic Resonance Spectroscopy 14Erlotinib Hydrochloride 14O(6)-benzylguanine 11Chemotherapy, Adjuvant 11Carboplatin 9sargramostim 8Thalidomide 8Imatinib Mesylate 8Filgrastim 8Surgical Procedures, Operative 6Gene Expression Profiling 6Drug Therapy 6pembrolizumab 5aldesleukin 5Topotecan 5Radiotherapy, Intensity-Modulated 5Hydroxyurea 5Gefitinib 5Etoposide 5Sorafenib 4Immunohistochemistry 4Dasatinib 4Celecoxib 4Biopsy 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Gliosarcoma × laromustine × Clear all
NCT00516282 2011-08-26

VNP40101M and Temozolomide in Treating Patients With Progressive or Relapsed Malignant Glioma

Northwestern University

Phase 1 Terminated
14 enrolled
CNSSarcoma

Astrocytoma, Glioblastoma, Glioma, Oligodendroglioma, Central Nervous System Neoplasms, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡